<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Netherlands Cancer Institute &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/netherlands-cancer-institute/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 25 Oct 2026 02:12:48 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Netherlands Cancer Institute &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Five Years Without Recurrence: Short-Course Immunotherapy Reshapes dMMR Colon Cancer Care</title>
		<link>https://bioengineer.org/five-years-without-recurrence-short-course-immunotherapy-reshapes-dmmr-colon-cancer-care/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sun, 25 Oct 2026 02:12:48 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[checkpoint inhibitors]]></category>
		<category><![CDATA[circulating tumor DNA]]></category>
		<category><![CDATA[colon cancer]]></category>
		<category><![CDATA[disease-free survival]]></category>
		<category><![CDATA[dMMR]]></category>
		<category><![CDATA[ipilimumab]]></category>
		<category><![CDATA[Neoadjuvant immunotherapy]]></category>
		<category><![CDATA[Netherlands Cancer Institute]]></category>
		<category><![CDATA[NICHE-2 trial]]></category>
		<category><![CDATA[nivolumab]]></category>
		<category><![CDATA[organ preservation]]></category>
		<category><![CDATA[Pathological Complete Response]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=452711</guid>

					<description><![CDATA[Long-term results from the phase 2 NICHE-2 trial show that none of 111 patients with dMMR colon cancer treated with four weeks of neoadjuvant nivolumab and ipilimumab experienced disease recurrence, with all patients alive at a median postoperative follow-up of 58.7 months.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">452711</post-id>	</item>
	</channel>
</rss>
